[go: up one dir, main page]

NO20050771L - Bicifadinformulering - Google Patents

Bicifadinformulering

Info

Publication number
NO20050771L
NO20050771L NO20050771A NO20050771A NO20050771L NO 20050771 L NO20050771 L NO 20050771L NO 20050771 A NO20050771 A NO 20050771A NO 20050771 A NO20050771 A NO 20050771A NO 20050771 L NO20050771 L NO 20050771L
Authority
NO
Norway
Prior art keywords
composition
release portions
bicifadinformulering
bicifadine
salts
Prior art date
Application number
NO20050771A
Other languages
English (en)
Inventor
Janet Codd
Brian Boland
Original Assignee
Nascime Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascime Ltd filed Critical Nascime Ltd
Publication of NO20050771L publication Critical patent/NO20050771L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

Det er beskrevet en fremgangsmåte og sammensetning for oral administrering av en enhetsdoseformsammensetning som inneholder bicifadin og salter derav, hvor sammensetningen inneholder porsjoner for kontrollert frigjøring og øyeblikkelig frigjøringsporsjoner.
NO20050771A 2002-07-31 2005-02-11 Bicifadinformulering NO20050771L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39985202P 2002-07-31 2002-07-31
PCT/IB2003/003700 WO2004012722A2 (en) 2002-07-31 2003-07-21 Bicifadine formulation

Publications (1)

Publication Number Publication Date
NO20050771L true NO20050771L (no) 2005-03-31

Family

ID=31495768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050771A NO20050771L (no) 2002-07-31 2005-02-11 Bicifadinformulering

Country Status (15)

Country Link
US (1) US20040127541A1 (no)
EP (1) EP1539148A2 (no)
JP (1) JP2005537295A (no)
KR (1) KR20050035250A (no)
CN (1) CN1684681A (no)
AU (1) AU2003253198A1 (no)
CA (1) CA2493593A1 (no)
IL (1) IL166478A0 (no)
MX (1) MXPA05001127A (no)
NO (1) NO20050771L (no)
NZ (1) NZ538519A (no)
PL (1) PL375086A1 (no)
RU (1) RU2005105302A (no)
WO (1) WO2004012722A2 (no)
ZA (1) ZA200501541B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569887B2 (en) 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
CN101389315A (zh) * 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
KR101733180B1 (ko) 2005-07-27 2017-05-08 뉴로반스, 인크. 신규 1-아릴-3-아자바이사이클로［3.1.0］헥산：제조 방법 및 신경 정신 질환 치료를 위한 용도
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196120A (en) * 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
US4231935A (en) * 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
ZA200501541B (en) 2006-08-30
RU2005105302A (ru) 2005-08-27
AU2003253198A1 (en) 2004-02-23
CA2493593A1 (en) 2004-02-12
NZ538519A (en) 2008-05-30
KR20050035250A (ko) 2005-04-15
WO2004012722A2 (en) 2004-02-12
US20040127541A1 (en) 2004-07-01
IL166478A0 (en) 2006-01-15
MXPA05001127A (es) 2005-10-18
JP2005537295A (ja) 2005-12-08
WO2004012722A3 (en) 2004-04-08
CN1684681A (zh) 2005-10-19
PL375086A1 (en) 2005-11-14
EP1539148A2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
NO20052479L (no) Tramadolformuleringer med forsinket frigjoring og 24 timers effektivitet
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20051389L (no) Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler
IS8885A (is) Lyfjablanda á föstu formi til til inntöku sem felur í sér S1P viðtakaörva og sykuralkóhól
NO20052761L (no) Spirocykliske cykloheksanderivater.
NO20045065L (no) Nytt formatsalt av o-desmetyl-venlafaxin
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
NO20050771L (no) Bicifadinformulering
NO20042361L (no) Form av 3-[(2{4-(Heksyloksykarbonylamino-imino-metyl)-fenylami no]-metyl}-1- metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral
NO20061432L (no) N3 alkylerte benzimidazolederivater som MEK-inhibitorer
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
NO20065904L (no) Terapeutiske forbindelser
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20045222L (no) Benzosyrederivater som modulatorer av PPAR alfa og gamma
NO20004818L (no) Stabile doseringsformer av fluoxetin og dets enantiomere
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
TW200508199A (en) Novel compound
NO20052182L (no) Nye forbindelser
ATE390128T1 (de) Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application